PMID- 21114607 OWN - NLM STAT- MEDLINE DCOM- 20110516 LR - 20221207 IS - 1463-1326 (Electronic) IS - 1462-8902 (Linking) VI - 13 IP - 1 DP - 2011 Jan TI - Liraglutide provides similar glycaemic control as glimepiride (both in combination with metformin) and reduces body weight and systolic blood pressure in Asian population with type 2 diabetes from China, South Korea and India: a 16-week, randomized, double-blind, active control trial(*). PG - 81-8 LID - 10.1111/j.1463-1326.2010.01323.x [doi] AB - AIM: To assess and compare the efficacy and safety of liraglutide with those of glimepiride, both in combination with metformin for the treatment of type 2 diabetes in Asian population from China, South Korea and India. METHODS: A 16-week, randomized, double-blind, double-dummy, four-arm, active control trial was carried out. In total, 929 subjects with type 2 diabetes with a mean (+/-s.d.) age of 53.3 +/- 9.5 years, HbA(1)(c) of 8.6 +/- 1.0% and body weight of 68.1 +/- 11.7 kg were randomized (liraglutide 0.6, 1.2 or 1.8 mg once daily or glimepiride 4 mg once daily all in combination with metformin: 1 : 1 : 1 : 1). One subject withdrew immediately after randomization and before exposure. RESULTS: HbA(1)(c) was significantly reduced in all groups compared with baseline. Treatment with liraglutide 1.2 and 1.8 mg was non-inferior to glimepiride (mean HbA(1)(c) reduction: 1.36% points, 1.45% points and 1.39% points, respectively). No significant difference was shown in the percentage of subjects reaching American Diabetes Association HbA(1)(c) target <7% or American Association of Clinical Endocrinologists target